Tag Archives: carbapenem

Carbapenemase-producing Gram negatives – what are treatment options?

Guest posting from Professor Josh Davis, Infectious Diseases, John Hunter Hospital, NSW and Menzies Institute , Darwin, Dr Patrick Harris , NHMRC Early Career Fellow at The University of Queensland Centre for Clinical Research (UQCCR) Carbapenemase-producing Enterobacterales (CPE),  Pseudomonas aeruginosa and Acinetobacter baumannii are usually resistant to most other antibiotics in addition to meropenem.  Treatment […]

Sparing meropenem 101: what alternatives exist for the treatment of ESBL-producers?

Guest post: Patrick Harris, Staff Specialist in Microbiology, Central Laboratory, Pathology Queensland, Brisbane In a previous post we looked at bacteria that produce AmpC-type beta-lactamases, such as Enterobacter spp.  Perhaps a more familiar, and increasingly common, problem is presented by species such as E. coli or K. pneumoniae, which have acquired extended-spectrum beta-lactamase enzymes (or ‘ESBLs’).  […]

Sparing meropenem 101 – treatment of ESCPM species and AmpC betalactamases unpacked

Guest post: Patrick Harris, Staff Specialist in Microbiology, Central Laboratory, Pathology Queensland, Brisbane Infectious disease and microbiology trainees diligently learn about organisms that have a type of broad-spectrum beta-lactamase (i.e. an enzyme that can inactivate betalactam antibiotics) called ‘AmpC’.  These enzymes are encoded by a gene that is usually located on the chromosome of many Gram-negative […]

Case report: Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae

In northern NSW, we already face cases similar to that described below – infection with multi-drug resistant carbapenemase-producing Gram negative organisms.  The major global types of these organisms are named with acronyms that refer to the type of carbapenemase gene – KPC, NDM (New Delhi Metallobetalactamase), IMP (imipenemase) and others.  KPC-type organisms are prevalent in Greece, […]